臨床泌尿器科72巻1号

2018年01月発行

特集 腎癌に対する薬物療法─最新エビデンスを実臨床に活かす

腎癌に対する一次薬物療法─各薬剤の効果を最大化するための工夫

著者： 近藤恒徳¹

所属機関： ¹東京女子医科大学東医療センター泌尿器科

ページ範囲：P.18 - P.25

文献概要

▶ポイント

・転移性腎癌症例に対する全身治療の主流は分子標的治療薬であり，治療効果を最大限に上げるためには，薬剤選択の根拠をもつことが重要である．

・治療では，1st-lineの薬剤選択が予後に最も大きく影響する．そのときに考慮すべき因子は腫瘍縮小効果であり，これまでの臨床試験の結果からはスニチニブが最も有効な薬剤であると考えられる．

・実臨床では臨床試験とは異なり，患者背景は多岐にわたるため，柔軟に薬剤選択を行うことも必要である．

参考文献

1） Macleod LC, Tykodi SS, Holt SK, et al : Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. Urology 86 : 262─268, 2015

2） Lindskog M, Wahlgren T, Sandin R, et al : Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012 : Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urol Oncol 35 : 541 e15─e22, 2017

3） Motzer RJ, Escudier B, McDermott DF, et al : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373 : 1803─1813, 2015

4） 日本泌尿器科学会 （編） : 腎癌診療ガイドライン2017年版. メディカルレビュー社, 東京, 2017

5） Motzer RJ, Barrios CH, Kim TM, et al : Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 32 : 2765─2772, 2014

6） Wahlgren T, Harmenberg U, Sandstrom P, et al : Treatment and overall survival in renal cell carcinoma : a Swedish population-based study （2000-2008）. Br J Cancer 108 : 1541─1549, 2013

7） Grünwald V, McKay RR, Krajewski KM, et al : Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 67 : 952─958, 2015

8） Motzer RJ, Hutson TE, Tomczak P, et al : Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 : 3584─3590, 2009

9） Motzer RJ, Hutson TE, Cella D, et al : Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369 : 722─731, 2013

10） Escudier B, Szczylik C, Hutson TE, et al : Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27 : 1280─1289, 2009

11） Hutson TE, Bukowski RM, Rini BI, et al : Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer 110 : 1125─1132, 2014

12） Poprach A, Lakomy R, Bortlicek Z, et al : Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma : Data from Real-World Clinical Practice. Drugs & Aging 33 : 655─663, 2016

13） Kaymakcalan MD, Xie W, Albiges L, et al : Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy : Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer 122 : 411─419, 2016

14） Eichelberg C, Heuer R, Chun FK, et al : Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma : a retrospective outcome analysis. Eur Urol 54 : 1373─1378, 2008

15） Bukowski RM, Stadler WM, McDermott DF, et al : Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 78 : 340─347, 2010

16） Cecere SC, Rossetti S, Cavaliere C, et al : Pazopanib in Metastatic Renal Cancer : A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”. Front Pharmacol 7 : 287, 2016

17） Kim MJ, Park SH, Lee JL, et al : A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. BMC Urol 16 : 46, 2016

18） Escudier B, Porta C, Bono P, et al : Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma : PISCES Study. J Clin Oncol 32 : 1412─1418, 2014

19） Izzedine H, Rixe O, Billemont B, et al : Angiogenesis inhibitor therapies : focus on kidney toxicity and hypertension. Am J Kidney Dis 50 : 203─218, 2007

20） Eremina V, Jefferson JA, Kowalewska J, et al : VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 : 1129─1136, 2008

21） Launay-Vacher V, Ayllon J, Janus N, et al : Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol 29 : 492─494, 2011

22） Miyake H, Muramaki M, Imai S, et al : Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents. Target Oncol 11 : 329─335, 2016

23） Ishihara H, Kondo T, Fukuda H, et al : Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. Jpn J Clin Oncol, 2017 ［Epub ahead of print］

24） Fukuda H, Kondo T, Iida S, et al : Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma. Urol Oncol 34 : 338. e1─9, 2016

25） Kondo T, Takagi T, Kobayashi H, et al : Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Jpn J Clin Oncol 44 : 270─277, 2014

26） Atkinson BJ, Kalra S, Wang X, et al : Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 191 : 611─618, 2014

27） Bjarnason GA, Khalil B, Hudson JM, et al : Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy : correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol 32 : 480─487, 2014

28） Najjar YG, Mittal K, Elson P, et al : A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 50 : 1084─1089, 2014

29） Miyake H, Harada K, Miyazaki A, et al : Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib. Med Oncol 32 : 78, 2015